Navigation Links
Inverness Medical Innovations Announces Second Quarter 2008 Results
Date:7/29/2008

$313,944

Cost of revenue 169,266 (7,673)(b)(d)(e) 161,593

Gross profit 144,678 7,673 152,351

Gross margin 46% 49%

Operating expenses:

Research and development 24,119 (2,224)(b)(d) 21,895

Selling, general and

administrative 146,765 (57,528)(b)(c)(d) 89,237

Total operating expenses 170,884 (59,752) 111,132

Operating income (loss) (26,206) 67,425 41,219

Interest and other income

(expense), net (20,518) 13,663 (b)(f)(h) (6,855)

Income tax (benefit)

provision 3,205 6,798 (i) 10,003

Equity earnings of

unconsolidated

entities, net of tax 1,560 224 (b) 1,784

Net (loss) income $(48,369) $74,514 $26,145

Preferred stock dividends $- $-

Net (loss) income

available to common

stockholders - basic $(48,369) $26,145

Net (loss) income per

common share

Basic $(1.06) $0.57

Diluted $(1.06)(j) $0.55 (l)

Weighted average common shares

- basic 45,565 45,559

Weighted average common shares

- diluted 45,565 (j) 47,361 (l)

(a) In calculating net income or loss on an adjusted cash basis, the

Company excludes from net income or loss (i) certain non-cash charges,

including amortization expense and stock-based compensation expense, (ii)

non-recurring charges and income, and (iii) certain other charges and


'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Reportlinker.com announces that a new ... catalogue: ,, The Future of ... 2015, Pipeline Analysis and Reimbursement ... ,, Summary ,, The author ... of Orphan Diseases Therapeutics - Market Forecasts ...
(Date:12/15/2009)... diameter NeedleProbes™ for Atomic Force Microscopy (AFM) have been ... for studies at the liquid/air interface. The NeedleProbes’ cylindrical ... height, evaporation rate and viscosity - all in a single ... ... December 15, 2009 -- New, constant diameter NeedleProbes ...
(Date:12/15/2009)... -- The Center for Business Intelligence (CBI), ... to announce the full agenda for the ... Congress . The forum will take place ... 2010. ,, Over 1,500 senior-level Finance, Accounting, ... premier event since its inception, and this ...
(Date:12/15/2009)... Belgium, December 15 , ... Designed to Evaluate the Ability of,Cardiopoietic Cells to ... Cardio3 BioSciences, a leading Belgian biotechnology company specialising,in ... today that it has completed, two months ahead ... pivotal Phase II/III trial of C-Cure, a,unique stem ...
Breaking Biology Technology:Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 2Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 3Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 4Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 5Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 6Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 7Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 8Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 9Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 10Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 11Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 12Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 13Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 14Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 15Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 16Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 17Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 18New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 2New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 3CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3
... 2008 Caliper Life,Sciences, Inc. (Nasdaq: CALP ) ... be held on June 3, 2008, at 10:00 a.m. ... Hopkinton, Massachusetts. The record,date for Caliper stockholders entitled to ... Caliper Life Sciences, Caliper Life Sciences is a ...
... the Hyatt Regency Cambridge, ... Massachusetts, ... leading marketplace for expertise, and the Biotechnology Industry,Organization (BIO) announced an ... venture investment community,registered to attend the BIO National Venture Conference, with ...
... Findings Presented at the American College of Cardiology 57th Annual ... ... Vermillion,Inc. (Nasdaq: VRML ), a molecular diagnostics company, presented ... may aid in the diagnosis of peripheral artery disease,(PAD). The research ...
Other Biology Technology:Gerson Lehrman Group Extends Partnership With BIO to Provide Scientific Expertise for the First Annual BIO National Venture Conference 2Gerson Lehrman Group Extends Partnership With BIO to Provide Scientific Expertise for the First Annual BIO National Venture Conference 3Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease 2Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease 3
(Date:12/16/2009)... -- BIO-key International, Inc. (OTC Bulletin Board: ... and finger-based biometric identification solutions, announced that ... Special Shareholder Meeting held today approved the ... to Interact911 Mobile Systems Inc. Of the ... and 1.2% were opposed. ,, (Logo: ...
(Date:12/16/2009)... LONDON, Dec. 16 European Union ... protecting their borders, which are increasingly subjected ... High investment in advanced technology security and ... market. ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, ... http://www.aerospace.frost.com ), Border Security Market Assessment ...
(Date:12/15/2009)... environmental impacts, social dynamics, and production levels are ... of an agroecosystem. Positive or negative, these factors ... social groups to continuously adapt farming and food ... learning theory suggests that knowledge is gained as ... are especially valuable for environmental and agricultural educators ...
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 2Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 3Experiential learning teaches change and adaptation 2Institute Chastises Congress on Health Care Reforms Offers Five Point Program for Reducing Health Care Costs by 50 25 54406 1Institute Chastises Congress on Health Care Reforms Offers Five Point Program for Reducing Health Care Costs by 50 25 54406 2Top 10 Reasons Traveling Nurses Choose to Earn Their Bachelors Degree Online 54403 1Top 10 Reasons Traveling Nurses Choose to Earn Their Bachelors Degree Online 54403 2Top 10 Reasons Traveling Nurses Choose to Earn Their Bachelors Degree Online 54403 3Top 10 Reasons Traveling Nurses Choose to Earn Their Bachelors Degree Online 54403 4Terraboost Unveils Free H1N1 Risk Mitigation Product 54400 1Terraboost Unveils Free H1N1 Risk Mitigation Product 54400 2Terraboost Unveils Free H1N1 Risk Mitigation Product 54400 3
... For Immediate Release - A catalytic antibody discovery made ... of the upcoming acquisition of biotechnology venture CovX by ... that our scientific findings have found such a broad ... M.D., president of Scripps Research. "This development underlines the ...
... DALLAS Dec. 19, 2007 The division of ... UT Southwestern Medical Center has been awarded a five-year, ... to fund the Center of Research Translation, which will ... There are a limited number of these centers around ...
... Product Line Utilizes World,s Best Selling Silicon ... ... N.Y., Dec. 18 ,AuthenTec, Inc. (Nasdaq: AUTH ), the ... (OTC Bulletin Board: BMRX), a,leading provider of biometrically secured consumer ...
Other Biology News:Scripps Research discovery leads to broad potential applications in CovX-Pfizer deal 2Scripps Research discovery leads to broad potential applications in CovX-Pfizer deal 3Scripps Research discovery leads to broad potential applications in CovX-Pfizer deal 4Scripps Research discovery leads to broad potential applications in CovX-Pfizer deal 5UT Southwestern secures $5 million NIH grant for lupus research 2bioMETRX, Inc. Announces Integration of AuthenTec Fingerprint Sensor in smartTOUCH(TM) Product Line 2bioMETRX, Inc. Announces Integration of AuthenTec Fingerprint Sensor in smartTOUCH(TM) Product Line 3
Rabbit polyclonal to ATF4 (phospho S245) ( Abpromise for all tested applications). Antigen: Synthetic phosphopeptide derived from human ATF4 around the phosphorylation site of Serine 245. En...
Amino-acids and Derivatives Rabbit Anti-conjugated L-isoleucine Polyclonal Antibody...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Sheep polyclonal to Streptomycin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule: Streptomycin conjugated to BSA....
Biology Products: